Loading stock data…
BioStem Technologies, Inc. (BSEM)
$4.00+0.29 (+7.82%)
Market ClosedLast close Sep 8
BioStem Technologies, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioStem Technologies, Inc. in the Healthcare sector is trading at $4.00 with a market capitalization of $71M. Wall Street consensus targets $7.00 (1 analysts), implying a +75.0% move over the next 12 months. The stock is currently 52% below its 52-week high of $8.40, remaining 10.1% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +75.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q3 2025 | Q2 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|
| Total Revenue | $7.90M↓ | $10.47M↓ | $10.96M↓ | $102.87M↑ | $18.41M |
| Gross Profit | $4.84M↓ | $9.27M↓ | $10.28M↓ | $99.34M↑ | $14.17M |
| Operating Income | -$8.40M↓ | $1.45M↑ | $112,759↓ | $8.48M↓ | $9.29M |
| Net Income | -$8.97M↓ | $761,052↑ | $10,613↓ | $15.52M↑ | $6.82M |
Peer Comparison
JNJUNHPFE
Fundamentals
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix c...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$71.33M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
4.55
Beta
Defensive asset. Lower volatility than the S&P 500.
0.26
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
26.51%
Volume
Today's trading volume
389,579
Recent News
BioStem Technologies Eyes Surgical Growth, Manufacturing Shift After BioTissue Deal
BioStem Technologies (OTCMKTS:BSEM) outlined its strategy to expand in surgical applications, shift its revenue mix away from physician-office wound care and bring manufacturing of acquired products into its Florida facility. Chairman and CEO Jason Matuszewski said the company uplisted to the Nasda
BioStem Technologies Inc (BSEM) (Q2 2026) Earnings Call Highlights: Revenue Surges to $7. ...
BioStem Technologies Inc (BSEM) reports strong hospital-led growth and raises full-year outlook, while navigating a $10M milestone payment and planned manufacturing transition.
BioStem Technologies Q2 Earnings Call Highlights
BioStem Technologies (OTCMKTS:BSEM) reported second-quarter revenue of $7.9 million as the company continued its transition to a predominantly hospital-focused commercial model. Revenue increased from $6.1 million in the first quarter, supported by higher hospital sales, expanded commercial coverage
BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates
BioStem Technologies, Inc. (BSEM) delivered earnings and revenue surprises of -4.00% and +23.43%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of +23.53% and +17.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?